Treatment for chronic myeloid leukaemia (CML)

The aim of treatment is to put chronic myeloid leukaemia (CML) into remission and to maintain the remission. The main treatment for CML is tyrosine kinase inhibitors (TKIs).

About treatment for chronic myeloid leukaemia (CML)

The aim of treatment is to put chronic myeloid leukaemia (CML) into remission and keep it in remission. This means there are no signs of CML in your blood during a standard blood test, and you feel well. There are different levels of remission.

Treatments for CML are very effective, and remission can usually be maintained for many years. For many people, CML can be well controlled, and it will not shorten their life.

We understand that having treatment can be a difficult time for people. We're here to support you. If you want to talk, you can:

Types of treatment for chronic myeloid leukaemia (CML)

Most people with CML are treated with targeted therapies called tyrosine kinase inhibitors (TKIs). These block the action of the tyrosine kinase made by the leukaemia cells. You take them as tablets or capsules every day. There are several TKIs for CML.

  • Imatinib - this is the most commonly used TKI.
  • Nilotinib can be used in the chronic or accelerated phase if you cannot have imatinib.
  • Dasatinib can be used as a first treatment in the chronic phase, or if Imatinib is causing severe side effects or is not working.

Chemotherapy

If you have a very high level of white blood cells in your blood when you are first diagnosed, you may be given chemotherapy tablets for a few days before starting TKI treatment. This is usually only until the doctors check that a TKI will work for you.

Occasionally chemotherapy is used if CML is in the blast phase. A combination of 3 or 4 drugs are given into a vein (intravenously)

Stem cell transplant

Sometimes, your doctors may suggest chemotherapy followed by a stem cell transplant (sometimes called a bone marrow transplant). This might be if TKI treatment does not work, or if you are diagnosed in the blast phase. A stem cell transplant is an intensive treatment and it is not suitable for everyone.

Interferon alpha

If other treatments have not worked, some people may be given interferon alpha in the chronic phase of CML. Interferon alpha is a protein that the body normally makes during viral infections, such as flu. Scientists can make this protein in the laboratory, so it can be used as a treatment.

Doctors may also use it for women who need treatment and are pregnant or want to become pregnant.

You have interferon alpha as an injection under the skin using a very fine needle. You or a family member or friend can be taught how to give these injections, so you can have them at home.

Interferon alpha can cause different side effects. Some are like the symptoms of flu. Some of the side effects can be reduced by taking a mild painkiller, such as paracetamol, before the injection. Your doctor can give you more advice.

Clinical trials for CML

Leukaemia research trials are done to try to find new and better treatments for leukaemia. Trials done on patients are called clinical trials. These may be done to:

  • test new treatments, such as new chemotherapy drugs or targeted therapies
  • look at new combinations of existing treatments, or change the way they are given to make them more effective or to reduce side effects
  • compare the effectiveness of drugs used to control symptoms
  • find out how cancer treatments work
  • find out which treatments are the most cost-effective.

Trials are the only reliable way to find out if a different type of treatment is better than what is already available.

Fertility and chronic myeloid leukaemia (CML) treatment

Some cancer treatments can affect fertility (your ability to become pregnant or make someone pregnant) or harm a developing baby. Because of this you may be advised to use contraception to prevent a pregnancy. If you want to have children or think you may in the future, talk to your doctor about this as soon as possible. They can talk to you about the possible options for planning your treatment.

About our information

  • References

    Below is a sample of the sources used in our chronic myeloid leukaemia (CML). If you would like more information about the sources we use, please contact us at cancerinformationteam@macmillan.org.uk

    Smith G, Apperley J, Milojkovic D, et al. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. British Journal of Haematology, 2020; 191, 2, Available from https://b-s-h.org.uk/ [accessed on October 2020].

    Hochhaus A, Saussele S, Rosti G, et al. Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines. Annals of Oncology, 2017; 28 (suppl 4), iv41-iv51. Available from https://www.esmo.org/ [accessed on October 2020].


  • Reviewers

    This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer. It has been approved by Senior Medical Editor, Dr Anne Parker, Consultant Haematologist.

    Our cancer information has been awarded the PIF TICK. Created by the Patient Information Forum, this quality mark shows we meet PIF’s 10 criteria for trustworthy health information.

The language we use

We want everyone affected by cancer to feel our information is written for them.

We want our information to be as clear as possible. To do this, we try to:

  • use plain English
  • explain medical words
  • use short sentences
  • use illustrations to explain text
  • structure the information clearly
  • make sure important points are clear.

We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.

You can read more about how we produce our information here.

Date reviewed

Reviewed: 01 December 2020
|
Next review: 01 December 2023

This content is currently being reviewed. New information will be coming soon.

Trusted Information Creator - Patient Information Forum
Trusted Information Creator - Patient Information Forum

Our cancer information meets the PIF TICK quality mark.

This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.